CervoMed is a clinical-stage company developing neflamapimod, an oral p38-alpha inhibitor for dementia with Lewy bodies and other brain disorders; it is not approved.
CervoMed's case rests on neflamapimod in dementia with Lewy bodies. RewinD-LB did not confirm the primary clinical outcome overall, despite encouraging MRI and subgroup findings. The new tablet addresses formulation variability, and FDA removed the exposure limit, supporting planned higher twice-daily dosing. Advancement into Phase 3 still depends on securing funding, with partnering prioritized. June financings raised approximately $20.5 million gross; management projects runway through the third quarter of 2027 under its operating plan. Early open-label nfvPPA biomarker results provide another development opportunity.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: A partner funds the DLB Phase 3
Does CervoMed secure a partner providing sufficient funding to advance neflamapimod into the DLB pivotal trial?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
DLB partnership remains pivotal as publications reinforce neflamapimod's dosing rationale
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.